Serum Uric Acid in Patients with Parkinson’s Disease and Vascular Parkinsonism: A Cross-Sectional Study

Background: Elevation of serum uric acid (UA) is correlated with a decreased risk of Parkinson’s disease (PD); however, the association and clinical relevance of serum UA levels in patients with PD and vascular parkinsonism (VP) are unknown. Objective: We performed a cross-sectional study of 160 Chinese patients with PD and VP to determine whether UA levels in patients could predict the outcomes. Methods: Serum UA levels were divided into quartiles and the association between UA and the severity of PD or VP was investigated in each quartile. Results: The serum levels of UA in PD were significantly lower than those in normal subjects and VP. The serum UA levels in PD patients were significantly correlated with some clinical parameters. Strong correlations were observed in male PD patients, but significant correlations were observed only between UA and the non-motor symptoms (NMS) of burden of sleep/fatigue and mood in female PD patients. PD patients in the lowest quartile of serum UA levels had significant correlations between UA and the unified Parkinson’s disease rating scale, the modified Hoehn and Yahr staging scale and NMS burden for attention/memory. Conclusion: Our findings support the hypothesis that subjects with low serum UA levels may be more prone to developing PD and indicate that the inverse relationship between UA and severity of PD was robust for men but weak for women. Our results strongly imply that either low serum UA level is a deteriorative predictor or that serum UA level serves as an indirect biomarker of prediction in PD but not in VP patients.

[1]  Ying Jiang,et al.  The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson's Disease and Vascular Parkinsonism , 2011, PloS one.

[2]  Gang Wang,et al.  Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease , 2012, Progress in Neurobiology.

[3]  I. Schlesinger,et al.  Uric acid in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[4]  Y. Chan,et al.  Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. , 2010, Free radical biology & medicine.

[5]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[6]  A. Schapira OXIDATIVE STRESS IN PARKINSONS-DISEASE , 1995 .

[7]  W. Wurst,et al.  Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice , 2011, Experimental Neurology.

[8]  M. Walters,et al.  Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? , 2006, British journal of clinical pharmacology.

[9]  M. Pohja,et al.  Uric acid and cognition in Parkinson's disease: a follow-up study. , 2011, Parkinsonism & related disorders.

[10]  A. Hofman,et al.  Serum uric acid levels and the risk of Parkinson disease , 2005, Annals of neurology.

[11]  E. Esposito,et al.  Non-steroidal anti-inflammatory drugs in Parkinson's disease , 2007, Experimental Neurology.

[12]  M. Mattson,et al.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.

[13]  G. Bing,et al.  Striatal Neuroinflammation Promotes Parkinsonism in Rats , 2008, PloS one.

[14]  S. Przedborski Inflammation and Parkinson's disease pathogenesis , 2010, Movement disorders : official journal of the Movement Disorder Society.

[15]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[16]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[17]  J. Trojanowski,et al.  Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.

[18]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[19]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[20]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[21]  A. Lang A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials , 2011, Movement disorders : official journal of the Movement Disorder Society.

[22]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[23]  M. Mcdermott,et al.  The relationship between uric acid levels and Huntington's disease progression , 2010, Movement disorders : official journal of the Movement Disorder Society.

[24]  D. Spiegelman,et al.  Plasma urate and Parkinson's disease in women. , 2010, American journal of epidemiology.

[25]  A. Shankar,et al.  Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community‐based survey , 2010, Movement disorders : official journal of the Movement Disorder Society.

[26]  E. Hirsch,et al.  Protection of midbrain dopaminergic neurons by the end‐product of purine metabolism uric acid: potentiation by low‐level depolarization , 2009, Journal of neurochemistry.

[27]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[28]  Á. Chamorro,et al.  Prognostic Significance of Uric Acid Serum Concentration in Patients With Acute Ischemic Stroke , 2002, Stroke.

[29]  Melinda K. Kutzing,et al.  Altered Uric Acid Levels and Disease States , 2008, Journal of Pharmacology and Experimental Therapeutics.

[30]  R. Rosenfeld Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[31]  Z. Pei,et al.  Nonmotor symptoms are independently associated with impaired health‐related quality of life in Chinese patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[32]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[33]  R. Brinton,et al.  Mitochondria as therapeutic targets of estrogen action in the central nervous system. , 2004, Current drug targets. CNS and neurological disorders.

[34]  S. Kish,et al.  Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[35]  Hirotaka Matsuo,et al.  Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.

[36]  W. H. Church,et al.  Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation , 1994, Brain Research Bulletin.

[37]  Ying Xia,et al.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease , 2012, Progress in Neurobiology.

[38]  V. Trkulja,et al.  Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson's disease patients. , 2010, Parkinsonism & related disorders.

[39]  Andrew J Lees,et al.  Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.

[40]  J. Hare,et al.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.

[41]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.

[42]  H. Benamer,et al.  Vascular Parkinsonism: A Clinical Review , 2008, European Neurology.

[43]  N. Hattori,et al.  [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[44]  Á. Chamorro,et al.  Uric Acid Levels Are Relevant in Patients With Stroke Treated With Thrombolysis , 2011, Stroke.

[45]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[46]  M. Tansey,et al.  Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.

[47]  Honglei Chen,et al.  Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease , 2007 .

[48]  P. Mecocci,et al.  Antioxidant Profile and Early Outcome in Stroke Patients , 2000, Stroke.

[49]  A. Hofman,et al.  Serum uric acid and cognitive function and dementia. , 2008, Brain : a journal of neurology.